Item 2. Properties
ITEM 2. PROPERTIES
The following sets forth certain information relating to our campuses and corporate headquarters as of September 30, 2025. Many of the leases are renewable for additional terms at our option. Our facilities are utilized consistent with management’s expectations, and we believe such facilities are suitable and adequate for currently identifiable requirements and that additional space, if needed, can be obtained on commercially reasonable terms to meet any future requirements.
Location Brand Approximate Square Footage Leased or Owned Lease Expiration Date
Campus locations:
Arizona (Avondale & Phoenix) UTI 283,000 Owned N/A
California (Garden Grove) Concorde 45,000 Leased March 2032
California (Long Beach) UTI 137,000 Leased August 2030
California (North Hollywood) Concorde 35,000 Leased May 2027
California (Rancho Cucamonga) UTI 148,000 Leased September 2031
California (Sacramento) UTI 117,000 Leased February 2033
California (San Bernardino) Concorde 48,000 Leased March 2028
California (San Diego) Concorde 34,000 Leased December 2036
Colorado (Aurora) Concorde 55,000 Leased April 2026
Colorado (Denver) (1)
Concorde 63,000 Leased December 2037
Florida (Fort Myers) (2)
Concorde 20,000 Leased October 2032
Florida (Jacksonville) Concorde 46,000 Leased December 2027
Florida (Miramar) UTI 103,000 Leased March 2032
Florida (Miramar) Concorde 33,000 Leased April 2028
Florida (Orlando) UTI 154,000 Owned N/A
Florida (Orlando) UTI 34,000 Leased March 2031
Florida (Orlando) Concorde 41,000 Leased April 2030
Florida (Tampa) Concorde 30,000 Leased January 2027
Georgia (Atlanta) (3)
UTI 150,000 Leased May 2036
Illinois (Lisle) UTI 187,000 Owned N/A
Michigan (Canton) UTI 125,000 Leased April 2036
Mississippi (Southaven) Concorde 23,000 Leased March 2027
Missouri (Kansas City) Concorde 18,000 Leased June 2032
Missouri (St. Joseph) Concorde 50,000 Leased December 2036
New Jersey (Bloomfield) UTI 102,000 Leased December 2030
North Carolina (Mooresville) UTI 146,000 Leased October 2030
Oregon (Portland) Concorde 33,000 Leased July 2034
Pennsylvania (Exton) UTI 129,000 Leased October 2029
Tennessee (Memphis) Concorde 72,000 Leased August 2031
Texas (Austin) UTI 107,000 Leased October 2032
Texas (Dallas) Concorde 47,000 Leased March 2031
Texas (Dallas) UTI 109,000 Owned N/A
Texas (Dallas) (4)
UTI 31,000 Leased September 2035
38
Location Brand Approximate Square Footage Leased or Owned Lease Expiration Date
Texas (Houston) UTI 172,000 Owned N/A
Texas (Houston) UTI 54,000 Leased September 2029
Texas (Grand Prairie) Concorde 50,000 Leased January 2029
Texas (San Antonio) (3)
UTI 51,000 Leased June 2036
Texas (San Antonio) Concorde 48,000 Leased February 2033
Other locations:
Arizona (Phoenix) UTI and Corporate 21,000 Leased February 2027
Missouri (Overland Park) Concorde 8,000 Leased November 2030
(1) During fiscal 2025, we signed a lease agreement to relocate our Concorde campus in Aurora, Colorado to a new facility in Denver, Colorado. In connection with the relocation, we extended our existing lease in Aurora through April 2026. Construction has begun on the new Denver facility and we expect the relocation to be completed in April 2026.
(2) Concorde signed a new facility lease agreement during fiscal 2025 related to our partnership with Heartland Dental to construct a new co-branded campus in Fort Myers, Florida, which is expected to open in early fiscal 2026, pending regulatory approvals, and will bring the total number of Concorde campuses nationwide to 18. Construction began during the second quarter of 2025.
(3) During fiscal 2025, we announced the opening of two new UTI campuses during fiscal 2026 in San Antonio, Texas and Atlanta, Georgia. We recorded the related lease obligations during 2025 as we began our build-out of these facilities.
(4) To expand our program offerings at our UTI Dallas campus, we signed a new facility lease agreement during fiscal 2025. The expansion will accommodate approximately 1,000 additional students and introduce programs in airframe and powerplant, HVACR, and electrical, pending all regulatory approvals.